STTK
Shattuck Labs, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Shattuck Labs, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
No other changes.
No other changes.
No thesis.
Annual filing, covered
10-K parsed · Mar 5 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 5 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Shattuck Labs, Inc..
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Shattuck Labs, Inc..
Largest filed tie
—
| Manager | Value | % base | |
|---|---|---|---|
| T. Rowe Price | $93.2M | 15.89% | +36.16% |
| Adage Capital Partners GP | $56.4M | 9.61% | +74.86% |
| Redmile | $47.8M | 8.15% | +24.41% |
| Orbimed | $43.8M | 7.46% | 0.00% |
| Prosight | $41.3M | 7.05% | +19.05% |
| Manager | Value | % base | |
|---|---|---|---|
| T. Rowe Price | $93.2M | 15.89% | +36.16% |
| Adage Capital Partners GP | $56.4M | 9.61% | +74.86% |
| Redmile | $47.8M | 8.15% | +24.41% |
| Orbimed | $43.8M | 7.46% | 0.00% |
| Prosight | $41.3M | 7.05% | +19.05% |
Expected move
Inputsspot 5.15exp Mar 19ATM strike 5ATM straddle 4.90IV 215%
Shattuck Labs, Inc.
4.66
−0.49 · −9.57%